Recipient of federal assistance · HOUSTON, TX

MARKER THERAPEUTICS INC

MARKER THERAPEUTICS INC received $5.5M in federal grants and other assistance in FY2026, on 7 actions, +55% vs FY2025. It has no federal contracts in the loaded years. Since FY2022: $13.4M. Its largest awarding agency was Defense Health Agency ($4.2M).

Assistance · FY2026
$5.5M
New awards
2
Actions
7
Since FY2022
$13.4M
UEI
CK3KR85CSP23
Location
HOUSTON, TX
Businesses
Open in the explorerFederal grants & assistance

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

Assistance by fiscal year

  1. 519.8KFY2022
  2. 664.8KFY2023
  3. 3.2MFY2024
  4. 3.5MFY2025
  5. 5.5MFY2026

By type

  1. Grants$5.5M100%

Top programs · Awarding agencies

Obligations in FY2026.

Top programs

  1. 12.420 · Military Medical Research and Development$4.2M76%
  2. 93.395 · Cancer Treatment Research$665K12%
  3. 93.103 · Food and Drug Administration Research$645.5K12%

Awarding agencies

  1. Defense Health Agency$4.2M76%
    Department of Defense
  2. National Institutes of Health$665K12%
    Department of Health and Human Services
  3. Food and Drug Administration$645.5K12%
    Department of Health and Human Services

Largest awards

  1. GRANT, PHASE 2 TRIAL OF PATIENT-DERIVED MULTITUMOR-ASSOCIATED ANTIGEN-SPECIFIC T CELLS (MT-601) TO TREAT RELAPSED/REFRACTORY DIFFUSE LARGE…$4.2M
    12.420 · Military Medical Research and Development· Defense Health Agency· Project grant· Jul 24, 2026 – Jul 24, 2026· HT9425261E440
  2. CONTROLLING TUMOR IMMUNE ESCAPE IN PANCREATIC CANCER USING A DUAL T CELL PRODUCT STRATEGY - ABSTRACT WHILE T CELL THERAPIES HAVE SHOWN…$2M
    93.395 · Cancer Treatment Research· National Institutes of Health· Project grant· Jun 14, 2024 – Aug 21, 2026· R44CA287653
  3. A PHASE 1 STUDY OF PATIENT-DERIVED MULTI-TUMOR-ASSOCIATED ANTIGEN SPECIFIC T CELLS (MT-601) ADMINISTERED TO PATIENTS WITH RELAPSED…$2M
    93.395 · Cancer Treatment Research· National Institutes of Health· Project grant· Aug 8, 2024 – Jul 20, 2026· R44CA291521
  4. PHASE 2 CLINICAL TRIAL OF A NOVEL T CELL THERAPY FOLLOWING BRIDGING THERAPY WITH HYPOMETHYLATING AGENTS FOR RELAPSED AML PATIENTS POST-STEM…$2M
    93.395 · Cancer Treatment Research· National Institutes of Health· Project grant· Aug 8, 2023 – Aug 12, 2026· R44CA285177
  5. A PHASE 1 STUDY OF PATIENT-DERIVED MULTI-TUMOR ASSOCIATED ANTIGEN SPECIFIC T CELLS (MT-601) ADMINISTERED TO PATIENTS WITH METASTATIC…$1.3M
    93.395 · Cancer Treatment Research· National Institutes of Health· Project grant· Aug 30, 2024 – Aug 20, 2026· R44CA295168
  6. EFFICACY OF A MULTI-TUMOR-ASSOCIATED ANTIGEN-SPECIFIC T CELL THERAPY IN AML PATIENTS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANT WITH MINIMAL…$1.2M
    93.103 · Food and Drug Administration Research· Food and Drug Administration· Project grant· Sep 8, 2022 – Apr 17, 2026· R01FD007272

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2022–FY2026.